You just read:

US Dermatologists Report a Sizeable Portion of Their Atopic Dermatitis Patients Currently Treated with Sanofi/Regeneron's Dupixent Would be Switched to Another Targeted Therapy if Available

News provided by

Spherix Global Insights

May 14, 2019, 11:36 ET